Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)Active Not Recruiting
NCT04626518Phase 1, Phase 2Updated Jul 30, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
United States, Australia, Canada, Chile, France +8 more
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)Active Not Recruiting
NCT04626479Phase 1, Phase 2Updated Jul 30, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
United States, Australia, Canada, Chile, Colombia +9 more
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)Active Not Recruiting
NCT05464030Phase 1Updated Jul 30, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Colorectal Cancer
United States, Canada, Japan, South Korea, Spain
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by SurgeryActive Not Recruiting
NCT04195399Phase 2Updated Jul 30, 2026
Sponsor: Children's Oncology Group
Desmoid Fibromatosis · Recurrent Desmoid Fibromatosis · Unresectable Desmoid Fibromatosis
United States, Australia, Canada, New Zealand, Puerto Rico
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLCRecruiting
NCT06745882Phase 2Updated Jul 30, 2026
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer
United States
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)Recruiting
NCT06170788Phase 3Updated Jul 30, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
United States, Argentina, Australia, Brazil, Canada +21 more
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR MutationsCompleted
NCT05258279Phase 2Updated Jul 29, 2026
Sponsor: Juntendo University
Non-squamous Non-small-cell Lung Cancer · EGFR Activating Mutation
Japan
New Assessment System in Measuring Symptom Distress in Cancer PatientsRecruiting
NCT00505245N/AUpdated Jul 29, 2026
Sponsor: M.D. Anderson Cancer Center
Caregiver · Health Care Provider · Malignant Neoplasm · Physician
United States
A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)Not Yet Recruiting
NCT07734610Phase 1Updated Jul 29, 2026
Sponsor: Merck Sharp & Dohme LLC
Severe Renal Impairment · Healthy
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC PatientsNot Yet Recruiting
NCT07004413Phase 3Updated Jul 29, 2026
Sponsor: Charite University, Berlin, Germany
Colorectal Cancer Metastatic
Germany
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)Active Not Recruiting
NCT03425643Phase 3Updated Jul 29, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +20 more
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS TumorsTerminated
NCT05081180Phase 1Updated Jul 29, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Central Nervous System Tumors
Canada, France, Germany, South Korea
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)Recruiting
NCT04198766Phase 1, Phase 2Updated Jul 29, 2026
Sponsor: Inhibrx Biosciences, Inc
Solid Tumor · Non-Small Cell Lung Cancer · Head and Neck Cancer · Melanoma
United States, Singapore, South Korea, Taiwan
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyActive Not Recruiting
NCT01874353Phase 3Updated Jul 29, 2026
Sponsor: AstraZeneca
Platinum Sensitive · BRCA Mutated · Relapsed Ovarian Cancer · Following Complete or Partial Response to Platinum Based Chemotherapy
United States, Australia, Belgium, Brazil, Canada +12 more
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruiting
NCT07327229Phase 1, Phase 2Updated Jul 29, 2026
Sponsor: Antengene Biologics Limited
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
China
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyRecruiting
NCT05756569Phase 2Updated Jul 29, 2026
Sponsor: Emory University
Bladder Squamous Cell Carcinoma · Locally Advanced Bladder Carcinoma · Malignant Renal Pelvis Neoplasm · Malignant Ureter Neoplasm
United States
Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)Completed
NCT05282901Phase 2Updated Jul 28, 2026
Sponsor: Institut Curie
Metastatic Uveal Melanoma
France
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL AdenocarcinomaActive Not Recruiting
NCT04069273Phase 2Updated Jul 28, 2026
Sponsor: Harry H Yoon
Gastric Cancer · GastroEsophageal Cancer · Adenocarcinoma
United States
A Study of Pembrolizumab in People With Ultra-Rare SarcomasRecruiting
NCT07089992Phase 2Updated Jul 28, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Sarcoma
United States
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)Active Not Recruiting
NCT05599789Phase 2Updated Jul 28, 2026
Sponsor: Peking Union Medical College Hospital
Non Small Cell Lung Cancer Metastatic
China
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic AlterationsActive Not Recruiting
NCT06644768Phase 1, Phase 2Updated Jul 28, 2026
Sponsor: Daiichi Sankyo
Non-small Cell Lung Cancer · Lung Cancer
United States, Argentina, Brazil, China, Japan
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)Terminated
NCT03598608Phase 1, Phase 2Updated Jul 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Hodgkin Disease · Lymphoma, Non-Hodgkin · Lymphoma, B-Cell
United States, Australia, Canada, Germany, Israel +1 more
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal CancerRecruiting
NCT06493019Phase 2Updated Jul 28, 2026
Sponsor: Dustin Deming
Anal Cancer
United States
Tailored Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients With Heart FailureCompleted
NCT06847438NAUpdated Jul 28, 2026
Sponsor: Emory University
Heart Failure
United States
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerRecruiting
NCT06161025Phase 2, Phase 3Updated Jul 28, 2026
Sponsor: Daiichi Sankyo
Solid Cancer
United States, Australia, Brazil, Canada, China +14 more

Previous page Next page